| Entry |
|
|---|
| Name |
First/second-generation tyrosine kinase inhibitor to EGFR mutation
|
|---|
| Definition |
(Gefitinib,Erlotinib,Afatinib,Dacomitinib) -| EGFR* |
|---|
| Expanded |
(D01977,D04023,D09733,D10514) -| 1956v2 |
|---|
| Type |
Drug target
|
|---|
| Gene |
| 1956 | EGFR; epidermal growth factor receptor |
|
|---|
| Variant |
1956v2 EGFR mutation in non-small cell lung cancer
|
|---|
| Perturbant |
| D01977 | Gefitinib (first generation) |
| D04023 | Erlotinib (first generation) |
| D09733 | Afatinib (second generation) |
| D10514 | Dacomitinib (second generation) |
|
|---|
| Reference |
|
|---|
| Authors |
Liao BC, Lin CC, Yang JC |
|---|
| Title |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Sharma SV, Bell DW, Settleman J, Haber DA |
|---|
| Title |
Epidermal growth factor receptor mutations in lung cancer. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
